Jeffrey Wolf, MD
Hematology-Oncology · San Francisco, CANPI 1720077480
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $388,899 of the $407,234 with a category attached, or 95.5%. Amgen accounts for 86.4% of it on its own, with 14 other manufacturers making up the rest. Reporting peaked in 2021 at $361,894 and has fallen 99.4% since, to $2,249 in 2025. Among hematology-oncology clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 59 payments — averaging $6902.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$352K
- Adaptive Biotechnologies Corporation$50K
- BD$3K
- Janssen Research & Development, LLC$1K
- Jazz Pharmaceuticals Inc.$1K
- Actelion Pharmaceuticals US, Inc.$458
- plus $694 from 9 others
Across 1 payment — averaging $3908.50 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Amgen$4K
What the payments were for
- Consulting fees$388,89995%
- Speaking & faculty fees$15,5634%
- Grants$840%
- Travel & lodging$1,1570%
- Food & beverage$1,5160%
- Education$140%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 2 | $351,721 |
| Adaptive Biotechnologies Corporation | 25 | $49,747 |
| BD | 1 | $2,513 |
| Janssen Research & Development, LLC | 2 | $1,100 |
| Jazz Pharmaceuticals Inc. | 1 | $1,000 |
| Actelion Pharmaceuticals US, Inc. | 16 | $458 |
| Johnson & Johnson | 2 | $204 |
| Daiichi Sankyo Inc. | 1 | $138 |
| Sanofi | 1 | $84 |
| Legend Biotech USA Inc. | 2 | $79 |
| Bristol Myers Squibb | 1 | $69 |
| AbbVie | 2 | $45 |
| Novartis | 1 | $33 |
| Pharmacyclics LLC, An Abbvie Company | 1 | $27 |
| Acrotech Biopharma Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$407,234 in reported general payments places this provider in the 95th percentile of 53 hematology-oncology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| PomalystPomalidomide | 77 | $1,510,595 |
| RevlimidLenalidomide | 58 | $1,048,011 |
| VenclextaVenetoclax | 44 | $618,595 |
| Lenalidomide | 16 | $207,485 |
| XareltoRivaroxaban | 17 | $24,805 |
| Acyclovir | 80 | $2,188 |
| ValacyclovirValacyclovir Hcl | 21 | $1,391 |
| Gabapentin | 15 | $523 |
| Dexamethasone | 37 | $409 |
| Mirtazapine | 11 | $143 |
| Allopurinol | 15 | $115 |
| Lorazepam | 24 | $107 |
| Ondansetron Hcl | 12 | $99 |
| Zolpidem Tartrate | 12 | $54 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 13 | $24 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bristol Myers SquibbRevlimid | $69 | $1,048,01158 claims |
| AbbVieVenclexta | $45 | $618,59544 claims |
| Johnson & JohnsonXarelto | $204 | $24,80517 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 53 hematology-oncology providers in California.
Other hematology-oncology in San Francisco
- Ari BaronSan Francisco$705K
- Bertrand TuanSan Francisco$45K
- Xiaolin ZhuSan Francisco$112
- Noah YoungerSan Francisco$0
- Travis ZackSan Francisco$0
- Evan WalkerSan Francisco$0
- Annabel FrankSan Francisco$0
- James BerensonWest Hollywood$1M
- Haresh JhangianiFountain Valley$77K
- Mark ScholzMarina del Rey$62K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.